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Abstract 38 
 39 
Background 40 
Wide variation exists in inter-hospital survival from out-of-hospital cardiac arrest (OHCA). 41 
Regionalisation of care into cardiac arrest centres (CAC) may improve this. We report a pilot 42 
randomised trial of expedited transfer to a CAC following OHCA without ST-elevation. The objective 43 
was to assess the feasibility of performing a large-scale randomised controlled trial. 44 
 45 
Methods 46 
Adult witnessed ventricular fibrillation OHCA of presumed cardiac cause were randomised 1:1 to either: 47 
1) treatment: comprising expedited transfer to a CAC for goal-directed therapy including access to 48 
immediate reperfusion, or 2) control: comprising current standard of care involving delivery to the 49 
geographically closest hospital. The feasibility of randomisation, protocol adherence and data collection 50 
of the primary (30-day all-cause mortality) and secondary (cerebral performance category (CPC)) and 51 
in-hospital major cardiovascular and cerebrovascular events (MACCE)) clinical outcome measures 52 
were assessed.  53 
 54 
Results 55 
Between November 2014 and April 2016, 118 cases were screened, of which 63 patients (53%) met 56 
eligibility criteria and 40 of the 63 patients (63%) were randomised. There were no protocol deviations in 57 
the treatment arm. Data collection of primary and secondary outcomes was achieved in 83%. There 58 
was no difference in baseline characteristics between the groups: 30-day mortality (Intervention 9/18, 59 
50% vs. Control 6/15, 40%; P=0.73), CPC 1/2 (Intervention 9/18, 50% vs. Control 7/14, 50%; P>0.99) or 60 
MACCE (Intervention 9/18, 50% vs. Control 6/15, 40%; P=0.73). 61 
 62 
Conclusions 63 
These findings support the feasibility and acceptability of conducting a large-scale randomised 64 
controlled trial of expedited transfer to CAC following OHCA to address a remaining uncertainty in post-65 
arrest care.  66 
 67 
Trial Registration: ISRCTN 96585404 68 
 69 
 70 
 71 
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 75 
Introduction 76 
Out-of-hospital cardiac arrest (OHCA) is a global public health issue. There are 60,000 OHCA per year 77 
in the United Kingdom and over 400,000 in the United States.1-3 There is wide variation in both regional 78 
and inter-hospital survival rates from OHCA and overall survival remains poor, with a reported average 79 
of 7%.4 The adoption of systematic approaches to post-resuscitation care may improve long-term 80 
survival from OHCA.5,6 Regionalisation of care into specialist centres has played a vital role in the 81 
management of time-critical illnesses through concentration of services and greater provider 82 
experience.7-14 Coronary artery disease is responsible for >70% of OHCA, with an acute occlusion 83 
demonstrated in 50% of consecutive patients taken immediately to coronary angiography.15 Multi-84 
faceted interventions including early cardiopulmonary resuscitation (CPR) and defibrillation, followed by 85 
timely reperfusion are associated with reduced risk of re-arrest, reduced myocardial dysfunction and 86 
thus improved outcomes following cardiac arrest from ST-elevation (STE) myocardial infarction.16-18 The 87 
International Liaison Committee on Resuscitation (ILCOR) suggests transport of all post-arrest patients 88 
to a cardiac arrest centre (CAC) with 24/7 access to interventional cardiology facilities to manage the 89 
ensuing cardiovascular dysfunction and to diagnose and treat the underlying cause with a view to 90 
increasing survival.19-22 The management of cardiac arrest survivors without STE, however, is 91 
controversial, with a less time-sensitive approach to cardiac catheterisation. Because of the lack of 92 
randomised data, there has been variable uptake of such a strategy amongst the interventional 93 
cardiology community. ILCOR states that randomised trials are therefore essential in this population to 94 
determine if timely delivery to a CAC improves survival.23 However, the coordination of this is complex 95 
and close interaction is necessary between centres and ambulance services and internally between the 96 
emergency department, cardiologists and the critical care team. We performed A (pilot) Randomised 97 
tRial of Expedited transfer to a cardiac arrest centre for non-ST elevation OHCA (ARREST) of 98 
presumed cardiac cause to assess the safety and feasibility of conducting a large-scale randomised 99 
controlled trial in patients without STE. 100 
 101 
Methods 102 
This was a pilot multi-centre prospective randomised controlled trial undertaken in London, United 103 
Kingdom by London Ambulance Service (LAS) and St Thomas Hospital (for system characteristics see 104 
online supplemental information). All adult witnessed out-of-hospital pulseless ventricular tachycardia 105 
(VT) or ventricular fibrillation (VF) cardiac arrests without obvious non-cardiac cause (trauma, drowning, 106 
suicide, poisoning) attended by the advanced paramedic practitioners in a pre-hospital setting were 107 
considered eligible for inclusion. Randomisation was performed following 3 cycles of CPR regardless of 108 
 4 
return of spontaneous circulation (ROSC). Refractory VF was defined as refractory to shock and drug 109 
treatment following 3 cycles of CPR. Patients were excluded from the trial if at the point of 110 
randomisation they had evidence of STE on the post-resuscitation ECG, the initial rhythm was asystole 111 
or pulseless electrical activity (PEA), a do not attempt resuscitation order was in place or suspected 112 
pregnancy. 113 
 114 
Before randomisation, patient management followed standard pre-hospital ALS guidelines. Eligible 115 
patients were randomly allocated with the use of sequentially numbered opaque, tamper-proof sealed 116 
envelopes (sealedenvelope.com) with pre-assigned random permuted blocks of ten, stratified according 117 
to site (advanced paramedic car). Randomisation was performed 1:1 to one of two parallel trial arms: 118 
intervention or control. The intervention arm consisted of activation of the pre-hospital triaging system 119 
(currently routinely in place for STE patients only) with pre-alert and delivery of the OHCA patient to the 120 
catheter laboratory at the dedicated CAC (24 hours a day, 7 days a week). Patients were transported to 121 
hospital with or without ROSC. Patients who achieved ROSC received guideline-recommended post-122 
resuscitation care including targeted temperature management (36°C 28 hours, followed by gradual 123 
rewarming at 0.5°C per hour)24 and goal-directed therapies. These included evaluation and 124 
identification of the underlying cause of arrest with access to immediate reperfusion if necessary and 125 
maintenance of normocapnia and normoxia with protective ventilation, optimisation of haemodynamics 126 
as well as maintenance of normoglycaemia.25 127 
 128 
The control arm comprised the current standard of pre-hospital care for patients with cardiac arrest of 129 
suspected cardiac aetiology as per LAS Cardiac Care Guidance Protocol (supplemental data). Patients 130 
were conveyed to the closest emergency department and management thereafter followed standard 131 
hospital protocol. In the absence of non-cardiac cause, and in the absence of futility, coronary 132 
angiography was recommended within 48-72 hours in the control arm if not performed sooner (evidence 133 
of STE or high-suspicion of on-going infarction at the discretion of the physician).  134 
 135 
The primary objective of this pilot trial was to assess the feasibility of a randomised trial in OHCA 136 
without STE comparing expedited transfer to a CAC with the current standard of care to assess a 137 
difference in 30-day mortality. Feasibility outcome measures included recruitment rate, protocol 138 
adherence and the ability to obtain case-report form specific data on participants. The primary clinical 139 
endpoint was 30-day all-cause mortality. Secondary clinical endpoints comprised 1) good neurological 140 
function at discharge, capped at 30 days according to the cerebral performance category (CPC), the 141 
most commonly used post-resuscitation outcome measurement for this purpose.26 2) The composite of 142 
in-hospital major adverse cardiovascular events (MACE) capped at 30 days, defined as: re-infarction27, 143 
further revascularisation and bleeding.  144 
 145 
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Prior to data analysis, the following additions were made to the trial secondary outcomes to capture all 146 
adverse events: 1) MACE was modified to include cerebrovascular events – termed MACCE. 2) Sepsis, 147 
defined as two or more components of the systemic inflammatory response syndrome.28 148 
 149 
Trained research staff at St Thomas Hospital collected trial related data. The trial was managed and 150 
coordinated by the London School of Hygiene and Tropical Medicine Clinical Trials Unit (LSHTM CTU). 151 
The study was granted ethical approval by the United Kingdom National Research Ethics Committee 152 
(REC 13/LO/1508). Due to the specific nature of the trial and the immediacy of the intervention, the 153 
committee waived the need for prior informed consent.  At the earliest appropriate time, the participant 154 
or their legal surrogate were asked for delayed consent. The trial was prospectively registered with the 155 
International Standard Randomised Controlled Trials Registry (ISRCTN 96585404). 156 
 157 
Statistical Analysis 158 
Statistical analysis, based on intention to treat, was performed using StatPlus (AnalystSoft, USA) and 159 
Prism version 7.0 (GraphPad Software Inc, USA). The sample size (n=40) was selected to allow an 160 
assessment of the feasibility of recruitment and implementation of trial processes.29 The pilot study was 161 
not powered to detect important differences. However, categorical data were compared using Fisher’s 162 
exact test; continuous data were compared by 2-sample t-test. The treatment groups were compared 163 
for the primary endpoint of all-cause mortality 30-days after randomisation using odds ratios with 95% 164 
confidence intervals (CI). The Kaplan-Meier survival curves were drawn to assess differences between 165 
groups for the time to an event data examining all-cause mortality at 30 days. All p values were 2 sided. 166 
 167 
Results 168 
Patient Population and Feasibility 169 
118 cases were screened, of which 63 patients (53%) met eligibility criteria. Forty of the 63 patients 170 
(63%) were randomised over two separate time periods: November 2014 to March 2015 (10 patients) 171 
and August 2015 to February 2016 (30 patients). Full data were available on 36 patients (90%); reasons 172 
for exclusion are detailed in the patient flow diagram (Figure 1), displayed according to Consolidated 173 
Standards of Reporting Trials (CONSORT) recommendation. The trial was stopped at 40 patients 174 
because the planned sample size to assess trial feasibility was reached. All randomised patients 175 
completed the trial. All patients in the Intervention arm were delivered direct to St Thomas Hospital 176 
cardiac catheter lab; patients in the control arm were delivered to the emergency department (ED) in 177 
one of 6 hospitals in London: St. Thomas Hospital, St. Mary’s Hospital, Chelsea and Westminster 178 
Hospital, King’s College Hospital, Royal Free Hospital, Royal London Hospital. One patient in the 179 
control arm did not reach hospital (online supplement). After randomisation, 4 patients (10%) were 180 
found to meet exclusion criteria (the presence of ST-elevation on the post-resuscitation ECG). However, 181 
for the intention to treat analysis, all patients were analysed in the group they were randomised to 182 
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regardless of this or eventual crossover or other protocol deviation. Only one patient was identified as 183 
having a non-cardiac cause of arrest (end-stage renal failure) and did not survive to hospital. All other 184 
patients had a cardiac cause of arrest. One patient had aortic dissection that was managed within the 185 
specialist centre, ten patients were identified as having a scar-related arrhythmia either due to previous 186 
infarct or heart muscle disease (requiring implantable cardioverter defibrillator implantation on 187 
admission) and the rest were directly due to coronary artery disease.  188 
 189 
Baseline characteristics, the intervals from cardiac arrest to defined events and ambulance service 190 
interventions are shown in Table 1. There were no significant differences between the two treatment 191 
groups in terms of baseline characteristics and cardiac arrest background variables. All patients 192 
presented with witnessed VF out-of-hospital cardiac arrest. Three patients in each group had ventricular 193 
fibrillation that was refractory to shock and drug treatment and were transported to hospital without 194 
ROSC.  195 
 196 
Angiographic characteristics  197 
The coronary angiographic findings are summarised in Table 2. Time to coronary angiography was 198 
shorter in the intervention arm compared with the control arm (100 [75 to 113] versus 132 [93 to 187]; 199 
median difference 32, 95% CI -9 to 101; P=0.08). The incidence of culprit artery occlusion (responsible 200 
for the OHCA) was 44% in the intervention group versus 50% in the control group (OR 0.6, 95% CI 0.1 201 
to 2.3; P=0.7).  202 
 203 
Primary and Secondary Clinical Outcomes 204 
The primary clinical endpoint of 30-day all-cause mortality (Table 3) was similar between both study 205 
arms (Intervention 9/18, 50% vs. Control 6/15, 44%; OR 0.6, 95% CI 0.2 to 2.9; P=0.73). Good 206 
neurological function evaluated at discharge, capped at 30 days, was similar in both groups 207 
(Intervention 9/18, 50% vs. Control 7/15, 47%; OR 1.1, 95% CI 0.3 to 4; P>0.99) (online supplement). 208 
The secondary (clinical) composite endpoint of in-hospital MACCE occurred in 11/18 in the Intervention 209 
arm compared with 6/15 in the control arm (61% vs. 53% respectively; OR 1.4, 95% CI 0.4 to 4.9; 210 
P=0.73). One stroke occurred in the control arm, one patient in the intervention arm and two in the 211 
control arm underwent further revascularisation and minor bleeding occurred in one patient in the 212 
intervention arm. The secondary endpoint of 6-month all-cause mortality was 9/17 (53%) in the 213 
intervention arm and 6/10 (60%) in the control arm (OR 0.75, 95% CI 0.2 to 3.8; P>0.99). One third of 214 
patients in both groups developed sepsis. Vascular complications occurred in one patient in the control 215 
arm. Four patients in the intervention group and two patients in the control group required mechanical 216 
circulatory support in the form of intra-aortic balloon pump insertion. Length of stay was the same in the 217 
two groups (intervention: 4.5, versus control: 4.5, median difference 0, 95% CI -2 to 8; P=0.19). 218 
 219 
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The Kaplan-Meier 30-day survival curve is shown in Figure 2 (intervention versus control: HR 1.7, 95% 220 
CI 0.3 to 10.5; P=0.6). In both study arms, a marked attrition in survival was seen between Day 0 and 221 
Day 4, with 25% of patients dead in the Intervention arm and 17% in the Control arm (overall 21%). No 222 
further patients died between Day 4 and Day 30. Administration of amiodarone was associated with 223 
increased 30-day mortality (HR 11.5, 95% CI 1.04 to 126; P=0.04). Pre-hospital ROSC (HR 0.1, 95% CI 224 
0.01 to 0.7; P=0.02), and cardiac arrest in a public location (HR 0.05, 95% CI 0.004 to 0.45; P=0.01) 225 
were associated with a lower mortality. The performance of coronary angiography was found to 226 
negatively influence 30-day mortality (HR 0.15, 95% CI 0.03 to 0.71; P=0.02); however, after adjustment 227 
for pre-hospital factors, there was no influence on 30-day mortality (HR 0.41, 95% CI 0.05 to 3.5; 228 
P=0.4), Figure 3. 229 
 230 
Discussion 231 
We demonstrated that it is possible to complete a randomised controlled trial comparing a pre-hospital 232 
triage system involving delivery of the OHCA patient to a CAC with access to 24/7 interventional 233 
cardiology facilities and receipt of a post-cardiac arrest care bundle with the current standard of care in 234 
a population of OHCA patients without STE. The main finding of this pilot trial is that performing a large-235 
scale randomised controlled trial is safe, feasible and acceptable. The feasibility of randomisation was 236 
demonstrated as follows: (1) recruitment of all adult witnessed shockable OHCA of presumed cardiac 237 
cause exceeded the expected rate. (2) It was possible to set up a fast track, rapid intervention service in 238 
a single CAC 24/7. (3) Protocol adherence was excellent in the intervention arm. (4) Data completeness 239 
was acceptable with documentation of the primary outcome in 83% and secondary outcomes in 80%. 240 
 241 
Based on the findings of the trial pilot, the decision to exclude the refractory cohort from the main trial 242 
was made based on 1) logistical challenges of on-scene extrication, transport and performing coronary 243 
angiography during mechanical CPR (m-CPR). 2) Poor outcomes relative to the cohort of patients 244 
achieving ROSC. 3) The identification that this was a predictor of 30-day mortality. Furthermore, not all 245 
frontline vehicles carry m-CPR devices, which may prevent shock-refractory patients receiving the same 246 
treatment in the main trial. The PARAMEDIC trial (LUCAS m-CPR device) showed a 5% lower survival 247 
rate (significant) in patients with shockable rhythms who received mechanical CPR, although this was 248 
not the primary objective of the trial, and should be interpreted with caution.30 Furthermore, removal of 249 
this cohort will reduce the likelihood of post randomisation identification of STE (10%).  250 
 251 
Outcome was ascertained in 83%; to improve this we will make use of the NHS information centre; in 252 
the PARAMEDIC trial, this enabled 99% follow-up at 30-days.30 Where data cannot be collected in 253 
hospital we plan to make use of the London Ambulance Clinical Audit and Research Unit (CARU) and 254 
National Institute for Cardiovascular Outcomes Research (NICOR). Because of the geographical 255 
position of St Thomas Hospital, a large proportion of the standard of care arm were delivered to a CAC; 256 
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we anticipate that expanding the trial across London will reduce the proportion of patients in the control 257 
arm taken straight to the cardiac catheterisation laboratory. 258 
 259 
The International Liaison Committee on Resuscitation (ILCOR) suggests transport of all post-arrest 260 
patients to a cardiac arrest centre with 24/7 access to interventional cardiology facilities.19-22 There has 261 
been variable uptake of such a strategy in this cohort; this may be due in part to the lack of randomised 262 
data, the need for coordination of organised systems of care, and the heterogeneity of the non-STE 263 
population; thus emphasising the need for a randomised controlled trial.  264 
 265 
Our study is consistent with well-established predictors of survival, including ROSC pre-hospital and 266 
cardiac arrest in a public location. The predictor of mortality identified was administration of amiodarone, 267 
this is likely to represent refractory arrhythmia rather than the effect of amiodarone itself. These are 268 
supported by findings in the recently published “amiodarone versus lignocaine and placebo trial in 269 
OHCA”, where no difference in survival was shown, with a higher mortality in those with unwitnessed 270 
arrest.31 Coronary angiography was performed in all patients in the intervention group and just under 271 
80% of control, suggesting that coronary angiography was clinically indicated in the latter. The time to 272 
coronary angiography was shorter in the intervention arm because of immediate delivery to a CAC, but 273 
this did not reach statistical significance in these few patients. In those who underwent coronary 274 
angiography, significant coronary disease was identified in two thirds of patients, with a culprit lesion in 275 
just over half, which is consistent with published registry data.16,32 However should be interpreted with 276 
caution because this was a small patient cohort that may not be representative of the patient population. 277 
The findings from this pilot also suggest that the absence of STE on the post-arrest ECG does not 278 
exclude acute ischemia.15 The overall mortality, albeit low, is representative of the VF OHCA population 279 
that achieves ROSC pre-hospital and is consistent with previous figures published by the London 280 
Ambulance Service. 33 281 
 282 
Limitations 283 
This study was a pilot randomised trial to demonstrate safety and feasibility; the study was not powered 284 
to show a difference in 30-day mortality, neurological endpoints or the composite of in-hospital MACCE. 285 
The full planned trial with a sample size of 860, will aim to address these questions. The catchment 286 
area around St Thomas Hospital was small and may not be representative of the population. Although 287 
this pilot provided an indication of the underlying event rate and incidence of occlusive coronary artery 288 
disease, the effect size and therefore sample size calculations were based on a combination of studies. 289 
These included the above pilot findings, Pan-London Annual OHCA audit data, published registry data 290 
(incidence of occlusive disease in OHCA in absence of STE) and randomised trials of reperfusion 291 
therapy.13,33-35 Based on findings from the trial pilot, inclusion criteria were amended to remove the 292 
shock-refractory cohort from the main trial because logistical challenges of managing these patients, 293 
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and in order to reduce the likelihood of post-randomisation identification of STE. Delayed 294 
prognostication (≥72 hours) to prevent the premature withdrawal of life-sustaining treatment was not 295 
formally instituted in the pilot as this was not the current standard of care; however this will be 296 
mandated during the full trial.36  297 
 298 
Conclusions 299 
This pilot study demonstrated that a large-scale randomised trial comparing the delivery of a cardiac 300 
arrest patient without STE to the catheter laboratory at a dedicated cardiac arrest receiving centre with 301 
a view to immediate reperfusion and delivery of post-resuscitation care, compared with standard care, is 302 
safe and feasible. 303 
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